Case Clinic 3: A 29-Year-Old Caucasian Man With a History of Injected Drug Use

PROGRAM DESCRIPTION The opiate epidemic has led to a dramatic increase in the incidence of new, acute hepatitis C virus (HCV) infection in the United States since 2006—a trend that ...

PROGRAM DESCRIPTION
The opiate epidemic has led to a dramatic increase in the incidence of new, acute hepatitis C virus (HCV) infection in the United States since 2006—a trend that is closely associated with increases in injection drug use (IDU). Furthermore, co-infection with hepatitis B and human immunodeficiency virus is not uncommon. Clinicians are challenged to determine the optimal approach to treatment in these patients, which demands selecting the appropriate treatment regimen based on viral genotypes and subtypes as well as employing protocols that promote treatment efficacy and minimize the risk of HCV treatment resistance.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:Select the appropriate direct-acting antiviral (DAA) agent for hepatitis C virus (HCV) infection based on viral genotypes (and subtype) and associated complicationsIdentify the emergence of HCV resistance-associated substitutions (RASs; also known as resistance-associated variants [RAVs]) following treatment with selected DAA regimensImplement strategies, including the spectrum of molecular testing protocols, to identify and monitor disease progression and treatment efficacy and potentially avert HCV treatment resistance

---

Write the first review

Resource tags